Descriptive Study of Recombinant Human Insulin-Like Growth Factor for Osteoporosis in Werner's Syndrome
I. Assess the safety and efficacy of recombinant human insulin-like growth factor 1 in a patient with Werner's syndrome and osteoporosis.
|Study Design:||Allocation: Non-Randomized
Primary Purpose: Treatment
|Study Start Date:||May 1992|
PROTOCOL OUTLINE: The patient receives subcutaneous recombinant human insulin-like growth factor 1 daily for 7 months. The dose is adjusted according to the serum hormone level and biological markers of bone turnover.
Concurrent therapy includes a metabolic diet, calcium citrate, and estradiol.
|Study Chair:||Craig D. Rubin||University of Texas|